Privigen Use In Pregnancy & Lactation

human normal immunoglobulin


CSL Behring


Zuellig Pharma
Full Prescribing Info
Use In Pregnancy & Lactation
Pregnancy: Controlled clinical data on the use of Privigen in pregnant women are not available. Caution should therefore be exercised with regard to administration during pregnancy. IVIg products have been shown to cross the placenta, increasingly during the third trimester.
Extensive clinical experience of immunoglobulins suggests that no harmful effects on the course of the pregnancy, or on the foetus and the newborn child are to be expected.
Experimental studies of the excipient L-proline carried out in animals found no direct or indirect toxicity affecting pregnancy, embryonal or foetal development.
Breast-feeding: Immunoglobulins are excreted into the milk and may contribute to protecting the neonate from pathogens which have a mucosal portal of entry.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in